European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Association of preoperative infections, nasal Staphylococcus aureus colonization and gut microbiota with left ventricular assist device outcomes1334
Diabesity and heart failure with preserved ejection fraction: the picture is getting clearer242
Morphine in acute pulmonary oedema: a signal of harm but more questions than answers235
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme205
May 2023 at a glance: focus on pathophysiology, comorbidities and devices152
Issue Information147
Letter regarding the article ‘Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure’132
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’129
Issue Information128
Alcohol consumption and incident heart failure in men and women119
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the CANVAS and CREDENCE trials115
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock114
Can we trust a smartwatch ECG? Potential and limitations109
Current and novel biomarkers in cardiogenic shock109
107
Left atrial enlargement and biomarker profiles: Time for integration of biomarkers and echocardiography in heart failure prevention99
Hypoalbuminaemia and heart failure: A practical review of current evidence99
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management96
Global perspectives on heart failure with preserved ejection fraction: Unravelling regional variations in a complex syndrome93
Differences in heart failure with preserved ejection fraction management between care providers: an international survey89
Tailoring medical therapy for heart failure with preserved ejection fraction88
Effects of atrial fibrillation ablation on arrhythmia burden and ventricular function in end‐stage heart failure: Lessons from CASTLE‐HTx88
October 2023 at a glance: From prevention to diagnosis, prognosis and treatment of acute decompensation and comorbidities86
From prediction to prevention: The role of heart failure risk models86
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial85
Time and left ventricular function: the forgotten dynamic factor81
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials80
What's all the fuss about a new guideline?79
Designing clinical trials in heart failure with preserved ejection fraction: quality over quantity?77
Heart failure: age is no excuse for complacency76
Combination diuretic therapy for acute heart failure: ‘alone we can do so little; together we can do so much’75
75
Spironolactone, fibrosis and heart failure with preserved ejection fraction71
September 2022 at a glance67
Plasma markers to risk stratify for heart failure in atrial fibrillation62
Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction – time to think outside the heart61
Early changes in renal function after sodium–glucose cotransporter 2 inhibitor initiation in EMPEROR‐Reduced: the end of the dilemma?59
Issue Information58
Cause‐specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry57
Reply to ‘Digoxin and beta‐blockers in patients with heart failure’. Letter regarding the article ‘Clinical outcomes with digoxin vs. beta‐blocker for heart rate control in permanent atrial fibrillati56
Issue Information55
Quality over quantity: Assessing the need for multiple biomarkers in predicting heart failure outcomes55
Moving forwards from clinical trials to a more individualized management of treatments in heart failure? Great value of Doppler echocardiography data54
Optimizing heart rate with ivabradine in heart failure with reduced ejection fraction: Insights from a post‐hoc analysis of the SHIFT trial54
The frail patient and the frailing heart. Letter regarding the article ‘Barcelona Bio‐HF calculator version 3.0: recalibration and incorporation of sodium–glucose cotransporter 2 inhibitor 53
Exercise left atrial compliance: One more tool in the heart failure with preserved ejection fraction assistance toolbox?53
Change in ejection fraction and long‐term mortality in adults referred for echocardiography53
N‐terminal pro‐B‐type natriuretic peptide post‐discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study52
Comprehensive vasodilatation in women with acute heart failure: Novel insights from the GALACTIC randomized controlled trial52
Reply to ‘Vericiguat in heart failure with reduced ejection fraction: the right choice above all else? The answermay lie in time’52
Issue Information51
Can biomarkers help find the ‘sweet spot’ for treating patients with diabetes?51
Letter regarding the article ‘Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure’51
0.086724996566772